GlassScriptPhysician profile
Yen M Tran
NPI 1508817933
$3,161.59
in general payments reported to CMS, 2019-2025
29 companies · $487 in 2025
The $487 reported for 2025 was more than what 80% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $518 · 2020: $51.30 · 2021: $595 · 2022: $622 · 2023: $616 · 2024: $273 · 2025: $487.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,375.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,375.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,033.88 | 2019-2023 | Liletta, Lo Loestrin Fe, Orilissa |
| Amgen INC. | $339.83 | 2019-2025 | Krystexxa |
| Agile Therapeutics, INC. | $256.26 | 2021-2024 | Twirla |
| Mayne Pharma Commercial LLC | $232.35 | 2022-2025 | |
| Exeltis, USA INC. | $168.03 | 2019-2024 | Slynd |
| Therapeuticsmd, INC. | $153.59 | 2019-2022 | |
| Abbott Laboratories | $152.13 | 2025 | Freestyle Libre 3 |
| Pfizer INC. | $106.56 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $105.45 | 2023-2024 | Myfembree, Gemtesa |
| Astellas Pharma US INC | $90.28 | 2023-2025 | Veozah |
| Millicent US INC | $69.45 | 2025 | Femlyv |
| Avion Pharmaceuticals | $61.55 | 2019-2023 | Balcoltra |
| Evofem Biosciences, INC. | $44.97 | 2021 | |
| Mylan Pharmaceuticals INC. | $40.37 | 2021 | |
| Myovant Sciences INC. | $35.82 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon US, LLC | $26.28 | 2023 | Ethicon, Vistaseal |
| Organon LLC | $23.81 | 2024-2025 | Jada System |
| Ascend Therapeutics US, LLC | $23.14 | 2023 | |
| Sage Therapeutics, LLC | $21.42 | 2024 | |
| Daiichi Sankyo INC. | $21.31 | 2019 | |
| Duchesnay USA Incorporated | $19.63 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.37 | 2023 | |
| Hologic Sales and Service, LLC | $19.05 | 2019 | |
| Lilly USA, LLC | $18.31 | 2022 | |
| Axsome Therapeutics, INC. | $17.35 | 2023 | Auvelity |
| Coopersurgical, INC. | $17.27 | 2025 | Paragard T 380a |
| Lupin INC. | $16.92 | 2019 | |
| Exact Sciences Corporation | $15.46 | 2023 | Cologuard Collection Kit |
| Novo Nordisk INC | $11.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yen Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.